{"url_path":"/sec/plur/8-k/2026-07-14/item-8-01","section_key":"item-8-01","section_title":"Item 8.01 Other Events.**","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-07-14","source_url":"https://www.sec.gov/Archives/edgar/data/1158780/0001213900-26-077960-index.html","accession_number":"0001213900-26-077960","cik":"0001158780","ticker":"PLUR","issuer_name":"Pluri Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1158780/0001213900-26-077960-index.html","primary_entity_key":"0001158780","primary_entity_name":"Pluri Inc."},"word_count":688,"has_tables":true,"body_markdown":"** **\n\n \n\n \n\n** **\n\n**Item 8.01 Other Events.**\n\n \n\nAs previously disclosed, Pluri\nInc. (the “Company”), together with its subsidiaries, Pluri Biotech Ltd., incorporated under the laws of Israel, and Pluristem\nGmbH, incorporated under the laws of Germany, entered into a finance agreement with the European Investment Bank (“EIB”) providing\nfor up to €50 million in funding, of which only the first tranche of €20 million was disbursed in June 2021, and such amount\nbears interest at 4% per annum, and was scheduled to become repayable on June 1, 2026 (the “EIB Loan”). The Company also previously\ndisclosed that on April 21, 2026, the Company received notice from the EIB that the EIB was reserving all of its rights under the finance\nagreement while discussions concerning potential alternatives, including a possible extension of the maturity date, remained ongoing.\n\n \n\nOn May 28, 2026, the EIB confirmed\nto the Company that the parties remain engaged in constructive discussions in good faith with the objective of exploring a mutually agreed\nresolution regarding the EIB Loan. The EIB further advised that such discussions and negotiations were not expected to extend beyond July\n3, 2026, and that during that period, and without prejudice to any of the EIB’s rights and remedies, no enforcement action was contemplated\nwhile discussions remained ongoing.\n\n \n\nFollowing July 3, 2026, the\nCompany remained in active discussions with the EIB regarding a potential resolution of matters relating to the EIB Loan. In recent communications,\nthe EIB has indicated that discussions are advancing constructively and are subject to its internal approval process and legal review.\nNo assurance can be given that the required approvals will be obtained, that the parties will reach a definitive resolution, or that the\nEIB will continue to refrain from exercising remedies available to it under the finance agreement.\n\n \n\n**Cautionary Note Regarding\nForward-Looking Statements**\n\n \n\nThis Current Report on Form\n8-K contains express or implied forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995\nand other U.S. federal securities laws. Forward-looking statements include, but are not limited to, statements regarding ongoing discussions\nwith the EIB; the status of the EIB’s review and approval process; receipt of the required approvals; ongoing discussions and potential\nresolution of matters relating to the EIB Loan; and that the EIB will continue to refrain from exercising remedies available to it under\nthe finance agreement . Words such as “may”, “will”, “should”, “could”, “would”,\n“expect”, “intend”, “plan”, “believe”, “estimate”, “target”, “potential”,\n“continue”, “anticipate”, “seek”, and similar expressions are intended to identify forward-looking\nstatements, although not all forward-looking statements contain these identifying words.\n\n \n\nForward-looking statements\nare based on management’s current expectations and are subject to risks and uncertainties that could cause actual results to differ\nmaterially from those expressed or implied by these forward-looking statements. Risks and uncertainties include, among others, the outcome\nand timing of the Company’s ongoing discussions with the EIB regarding the EIB Loan, whether the EIB’s internal approval process\nand legal review will be completed, whether those discussions result in a mutually agreed resolution, the Company’s liquidity position\nand need for additional financing, general market and economic conditions, the possibility that the EIB may exercise remedies under the\nfinance agreement and other risks and uncertainties described under the heading “Risk Factors” in the Company’s most\nrecent Annual Report on Form 10-K and in other filings the Company makes with the U.S. Securities and Exchange Commission (the “SEC”).\nForward-looking statements speak only as of the date of this Current Report on Form 8-K. The Company undertakes no obligation to update\nor revise any forward-looking statements, whether as a result of new information, future events, or otherwise, except as required by law.\nFor a more detailed description of the risks and uncertainties affecting the Company, reference is made to the Company’s reports\nfiled from time to time with the Securities and Exchange Commission.\n\n \n\n1\n\n \n\n \n\n**SIGNATURES**\n\n \n\nPursuant to the requirements\nof the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto\nduly authorized.\n\n \n\n \n**PLURI INC.**\n\n \n \n\nDate: July 14, 2026\nBy:\n/s/ Liat Zalts\n\n \nName: \nLiat Zalts\n\n \nTitle:\nChief Financial Officer\n\n \n\n \n\n2"}